Hello, I am | Scleroderma Medical News by Date | |
| February 2008 | |
| Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. This population-based cohort study provides evidence that the majority of patients with scleroderma and breast cancer have limited scleroderma and anti-centromere antibody. They also were found to have a higher incidence of a positive family history of breast cancer. (PubMed) Rheumatol Int. 2008 Feb 16. (Also see: Scleroderma and Cancer ) | |
| A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. In a population of patients with diffuse cutaneous systemic sclerosis, with progressive disease of recent onset, D-penicillamine treatment at a median dose of 750 mg per day caused a statistically significant reduction in skin involvement and improvement of renal, cardiac and pulmonary involvement. (PubMed) Br J Dermatol. 2008 Feb 16. (Also see: Scleroderma Treatments, Clinical Trials, and Skin Fibrosis ) | |
| Correction of facial linear scleroderma 'coup de sabre' with BoneSource®. Surgical outcome was excellent in cosmetic and functional aspects without any complication. The patient was followed for 36 months after the operation; the defect was satisfactorily corrected and no postoperative problems have been found. (PubMed) J Plast Reconstr Aesthet Surg. 2008 Feb 1. (Also see: En Coup de Sabre ) | |
| Risk Factors Associated with Pulmonary Arterial Hypertension (PAH) in Colombian Patients with Systemic Sclerosis (SSc): Review of the Literature. PAH may be a frequent complication of SSc in the Colombian population regardless of disease subtype. J Rheumatol 2008;35:244-50 (Also see: PAH ) | |
| Nursing problems of patients with systemic sclerosis. The main aim of individual nursing care is to alleviate ailments, prevent infections, observe life-threatening conditions and to educate the patient as regards self-care and self-observation. (PubMed) Adv Med Sci. 2007; 52 Suppl 1:147-52. (Also see: Disability Resources ) | |
| Treatment of complications associated with systemic sclerosis. Systemic sclerosis is characterized by various circulatory, dermatological, gastrointestinal, musculoskeletal, pulmonary, and renal complications. Although there is no cure for systemic sclerosis, management of its associated complications can help improve patients' quality of life. (PubMed) Am J Health Syst Pharm. 2008 Feb 15; 65(4):315-21. (Also see: About Scleroderma ) | |
| Systemic sclerosis and malignancy: a review of the literature. Malignancy is associated with systemic sclerosis in between 3.6 and 10.7% of patients diagnosed with systemic sclerosis. (PubMed) South Med J. 2008 Jan; 101(1):59-62. (Also see: Cancer and Scleroderma ) | |
| Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Besides topical and systemic therapy, UVA1 radiation is a good option of treatment in various skin diseases. It is one of the first-line treatments for several sclerotic diseases and it often improves pruritus considerably. (PubMed) Photodermatol Photoimmunol Photomed. 2008 Feb; 24(1):19-23. (Also see: Morphea and Scleroderma Treatments ) | |
| The effect of imatinib (Gleevec) on scleroderma and normal dermal fibroblasts: a preclinical study. This study suggests that imatinib can serve as therapy to limit dermal fibroblast proliferation in scleroderma. (PubMed) Dermatology. 2008; 216(2):109-17. (Also see: Clinical Trials and Skin Involvement ) |
|
|
||||||||||||||
| Keep on Surfing! | ||||||||||||||
| Go to Scleroderma Medical News: January 2008 | ||||||||||||||
|
||||||||||||||